Renal impairment in T2DM limits the available antidiabetic treatment options. The rationale for this trial was to establish the efficacy and safety of liraglutide (lira) as add-on to existing OAD and/or insulin therapy in subjects with inadequately controlled T2DM and moderate renal impairment (Stage 3 CKD) (eGFR 30-59 mL/min/1.73 m2; MDRD). In this 26-week, double-blind, randomised study, subjects received either once-daily lira 1.8 mg or placebo with a primary endpoint of change in A1c from baseline (BL) to Week -26 (see Table). Liraglutide showed superior glycaemic control relative to placebo in subjects with Stage 3 CKD with a low risk of hypoglycemia and reduced body weight. The most common AEs were GI side effects, mostly nausea and vomiting which resolved quickly, (lira 35.7%, placebo 17.5%) and there was a higher incidence of AE leading to withdrawals in the lira group (13.6%) compared to placebo (2.9%). No deterioration in renal function was observed (eGFR change from BL: -1% lira; +1% placebo). In summary, liraglutide showed superior A1c and weight reduction with no unexpected safety or tolerability issues including no worsening of renal function in subjects with Stage 3 CKD over 26 weeks. The efficacy, low incidence of hypoglycaemia and safety of liraglutide in subjects with T2DM and Stage 3 CKD was demonstrated.